Intervention Protocol

Melatonin in cancer treatment

  1. Elke Wolf1,†,
  2. Stefania Milazzo1,*,
  3. Karen Pilkington2,
  4. Jian Ping Liu3,
  5. Marcel Zwahlen4,
  6. Markus Horneber1

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 17 OCT 2012

DOI: 10.1002/14651858.CD010145

How to Cite

Wolf E, Milazzo S, Pilkington K, Liu JP, Zwahlen M, Horneber M. Melatonin in cancer treatment (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010145. DOI: 10.1002/14651858.CD010145.

Author Information

  1. 1

    Klinikum Nord, Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie, Nuernberg, Germany

  2. 2

    University of Westminster, School of Life Sciences, London, UK

  3. 3

    Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China

  4. 4

    University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland

  1. Deceased

*Stefania Milazzo, Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie, Klinikum Nord, Prof.-Ernst-Nathan-Str. 1, Nuernberg, 90340, Germany.

Publication History

  1. Publication Status: New
  2. Published Online: 17 OCT 2012




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and tolerability of melatonin for the treatment of cancer patients.